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Objectives
§ Describe the global and local epidemiology of
TB/HIV coinfection
§ Utilize TSTs and IGRAs appropriately in the
diagnosis of LTBI in people living with HIV
(PLWH)
§ Identify the signs and symptoms of active TB in
PLWH
§ Develop a treatment plan for an TB/HIV
coinfected patient
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TB Case Rates,* United States, 2016
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*Cases per 100,000; as of June 21, 2017.
DC, District of Columbia; NYC, New York City (excluded from New York state)

≤2.9 (2016 national average)
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https://www.cdc.gov/tb/statistics/surv/surv2016/default.htm

Coinfection (%)

Estimated HIV Coinfection Among Persons
Reported with TB, United States, 1993–2016*

* As of June 21, 2017.
Note: Minimum estimates are based on reported HIV-positive status among all TB patients in the age group.

https://www.cdc.gov/tb/statistics/surv/surv2016/default.htm

TB/HIV in Georgia, 2016
§ 301 new TB cases (2.9 cases per 100000)
§ 48% foreign-born persons
§ 11% HIV positive
- 80% non-Hispanic,
Black
- 73% male
- 50% age 45-64

**

*

HIV-positive by Health District:
1.1 Rome: 20% (5)
3.1 Cobb: 7% (29)
3.2 Fulton: 30% (44)
3.4 Lawrenceville: 11% (37)
3.5 DeKalb: 9% (58)
5.2 Macon: 11% (9)
6.0 Augusta: 17% (18)
7.0 Columbus: 6% (17)

HIV and Tuberculosis
§HIV increases the risk of TB
reactivation enormously.
§TST+, HIV- Þlifetime risk ~10%
§TST+, HIV+ÞYEARLY risk ~10%
§A deadly duo

TB Risk Factors in HIV
Sociodemographic:
§ Black, Asian or Hispanic
ethnicity
§ Birth or long-term
residence in a country with
high TB incidence
§ HIV acquisition through
IDU/ active IDU use
§ Homelessness
§ Proximity to active TB
case
Winter et al. IJTLD (7):713-722 · July 2018

Clinical:
§ Low CD4 count
§ High viral load
§ Failure of (or late) initiation
of ART

In addition to HIV…
§ TB disproportionately affects vulnerable populations:
recent immigrants, homeless, incarcerated or have
problems with substance abuse
§ These populations are “hard to reach” and are linked by
poverty, social deprivation and difficulty in accessing
health care

Barriers to Care
§ Stigma: may prevent patients from accepting supervised
treatment in their homes, where visits from health care
workers would be immediately noticed by the community; fear
of being laid off or fired if TB is discovered; loss of community
due to isolation; reluctance to disclose contacts can lead to
outbreaks
§ Lack of access to health care: lack of insurance, lack of
providers, distance to facility, no transportation, having to
choose between work and care
§ Distrust of medical community
§ Delays in correct TB diagnosis and initiation of effective TB
treatment increases TB morbidity/mortality, risk of
transmission and development of drug-resistant TB

TB Prevention
§ Early HIV diagnosis with early initiation of ART
§ ART results in a prompt and marked decrease in the
incidence of TB disease
§ HIV-related TB incidence has declined more rapidly
than the rate of active TB in the general population,
in part due to the widespread use of ART
§ Even with the beneficial effects of ART, the risk of TB
disease among persons with HIV infection remains
greater than that of the general population

TB Prevention--LTBI
§ Treatment of latent TB infection (LBTI) (as defined by a
positive tuberculin skin test [TST]) decreases the risk of
TB disease by 62% and the risk of death by 26% among
persons with HIV infection
§ Prevention of TB disease by screening and appropriate
treatment for LTBI are key components of HIV care

When to Test for LTBI
§ Test for LTBI at initiation of HIV care
§ Repeat LTBI testing:
-If initial test negative and subsequent CD4 cell count
rises to >200 cells/mm3
after the initiation of antiretroviral therapy

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
https://aidsinfo.nih.gov/guidelines

Repeat LTBI testing (if baseline test
negative) annually if there is ongoing high risk
for TB exposure:
§ Current or history of incarceration
§ Live in congregate settings
§ Active drug abuse (IVDA, crack cocaine)
§ Marginal housing or homelessness
§ Travel to TB-endemic locations

Tuberculin Skin Testing
§ Inject 0.1 ml of
standardized mix of TB
proteins (purified protein
derivative)
§ Given intradermally on
volar forearm
§ Measure induration 4872 hrs after placement
§ Measure in millimeters,
not “positive” or
“negative”
§ Should be interpreted by
well-trained health care
professional

Picture from: www.info.gov.hk/dh/
diseases/CD/TB.htm

Interpreting a Tuberculin Skin Test
(TST)

http://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm

Blood Tests for TB Infection
§ Interferon Gamma Release Assays (IGRA)
§ Developed in 2001
§ Measures the interferon gamma (IFN-γ) released in
response to M.tuberculosis antigens

Lancet 356: 1099 2000

IGRAs:
PROS:
§ Requires single patient visit
“One and done”
§ Results can be available within 24
hours
§ Does not boost responses measured
by subsequent tests
§ Prior BCG vaccination does not
cause a false-positive result
§ Largely unaffected by most
environmental nontuberculous
mycobacteria (NTM)
§ Data suggest not affected by
intravesicular BCG

CONS:
§ Expensive
§ Blood samples must be processed 8-30
hours after collection
§ Errors in collecting or transporting blood
specimens or in running and interpreting
the assay can decrease accuracy
§ Inconsistent test reproducibility
§ Limited data on effect of IGRA-guided
therapy on prevention of TB disease
§ False positive can occur in individuals
infected with: M. marinum, M. kansasii
§ May be boosted by TST (>3 days to 3
months)

FDA-Approved IGRAS: T-Spot, Quantiferon-TB Gold, Quantiferon-TB Gold Plus

IGRA Performance in Diagnosing
LTBI in HIV+ Patients
§ IGRAs (particularly TSPOT) may be more
sensitive than TST in HIV-affected individuals
and less affected by advanced
immunosuppression
§ IGRAs perform similarly to the TST in identifying
HIV+ individuals who could benefit from LTBI
therapy
§ Low TB screening completion rates with TST
may be improved by using IGRA
Cattamanchi et al. J Acquir Immune Defic Syndr 2011;56:230-238

IGRA vs.TST in HIV
§ No definitive comparisons of tests for LTBI screening in
persons with HIV in low-burden TB settings
§ Use one or the other, not both

LTBI testing of ANY kind is preferabl
to NO TESTING

Evaluation of LTBI in HIV
§ Assess for symptoms: fever,
night sweats, weight loss,
cough of any duration,
lymphadenopathy
§ CXR
§ Assess for extrapulmonary
TB:
-more common in HIV
-more common when
CD4<200

Who to treat?
§ A positive diagnostic test for LTBI and no prior
history of treatment for active or latent TB
§ A negative diagnostic test for LTBI but close
contacts of persons with infectious pulmonary
TB

Borisov AS, Bamrah Morris S, Njie GJ, et al. Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent
Mycobacterium tuberculosis Infection. MMWR Morb Mortal Wkly Rep 2018;67:723–726.

Diagnosis of Active TB in HIV
§ Presentation of disease influenced by degree of
immunodeficiency
§ In HIV+ without pronounced immunodeficiency
(CD4>350), TB clinically resembles disease seen in HIVnegativeàpulmonary disease with typical x-ray
§ Lower CD4 countsàatypical presentation of disease
§ Extrapulmonary TB is also more common in HIV
regardless of CD4 count:
-disseminated/miliary disease
-meningitis
-lymphadenitis
§ High level of suspicion necessary

Diagnosis of Pulmonary TB in HIV
§ Most HIV-infected
patients with pulmonary
TB have symptoms:
-fever, cough, weight
loss, night sweats
§ Duration of symptoms is
shorter in HIV-infected
patients
§ 25 % of HIV+ individuals
with pulmonary TB will
have negative TST or
IGRA
§ CXR atypical or even
normal with CD4 <200

• “Atypical” CXR findings
include: lower lobe, middle
lobe, interstitial or miliary
infiltrates

N Engl J Med 2010; 362:707-716
http://www.searo.who.int/EN/Section10/Section18/Section356/Section421_1626.htm

Diagnosis of Pulmonary TB in HIV
§ Obtain CXR
§ AFB sputum smear x 3
§ Nucleic-acid amplification testing: GeneXpert MTB/RIF,
GeneXpert MTB/RIF Ultra
§ Sputum for AFB culture and drug susceptibility

Daily Therapy
§ TB regimens that included twice- or thrice-weekly dosing
during the initial intensive phase of therapy have been
associated with an increased risk of treatment failure or
relapse with acquired rifampin resistance
§ Daily therapy is recommended over the entire course of
therapy via directly-observed therapy (DOT)

Video Directly Observed Therapy
§ The use of remote video by a healthcare provider to
observe a patient ingesting medications
§ North Carolina: in person DOT for at least first two weeks,
uses Facetime, Skype
§ Georgia: in person DOT for first 8 weeks, uses Skype

Georgia Tuberculosis Policy and Procedure Manual 2016 https://dph.georgia.gov/sites/dph.georgia.gov/files
N.C. Tuberculosis Policy Manual https://epi.publichealth.nc.gov/cd/lhds/manuals/tb/6

Timing of ART in TB/HIV Disease
§ Concurrent therapy is challenging due to:
-High pill burden
-increased potential drug toxicity
-increased risk of drug interactions
-risk of TB-associated IRIS
§ Delaying HAART until after completion of TB therapy
increases AIDS-associated morbidity and mortality

Timing of ART in TB/HIV Disease
§ CD4<50: start ART within two weeks of starting TB
therapy
§ CD4 ≥50: ART should be started within 8 weeks of
starting TB therapy
§ When TB occurs in patients already on ART, start TB
medications immediately and choose rifamycin that does
not lead to drug interactions with ART
**early ART not necessarily beneficial in TB meningitis

Adverse Drug Reactions in TB
Patients on ART
§ TB medications and antiretrovirals share similar adverse
drug reactions:
-drug-induced liver injury
-rash
§ Due to multiple medications, it may be difficult to
determine cause

TB-IRIS
§ Relatively common in patients starting ART while on TB
treatment (8%-43%)
§ Risk factors: CD4<100, extrapulmonary or disseminated
TB, short interval between starting TB meds and ART,
high viral load
§ Symptoms typically occur 1-4 weeks after ART initiated

ATS/CDC/IDSA Clinical Practice Guidelines for Drug-Susceptible TB. CID 2016:63 (1 October)

TB-IRIS
§ Patients usually improve on TB therapy, then
develop new or recurrent symptoms within the
first few weeks of ART
§ Common manifestations:
- fevers
- new or worsening lymphadenopathy
- new or worsening respiratory symptoms
- new or worsening radiographic findings
§ Diagnosis based on: clinical presentation with
typical timeline, demonstration of response to
ART (↑CD4, ↓VL), r/o alternative causes for
deterioration like: treatment failure from drug
resistant TB, other OIs
ATS/CDC/IDSA Clinical Practice Guidelines for Drug-Susceptible TB. CID 2016:63 (1 October)

TB-IRIS
§ Treatment:
-symptomatic; treat with anti-inflammatories
-most cases self-limiting
-steroids used in cases with significant symptoms:
prednisone 1.25 mg/kg/day for 2-4 weeks with tapering
over a period of 6-12 weeks or longer

ATS/CDC/IDSA Clinical Practice Guidelines for Drug-Susceptible TB. CID 2016:63 (1 October)

TB/HIV Pearls
§ Early diagnosis and treatment of HIV will help reduce TB
risk
§ Early assessment for latent TB infection and treatment (if
indicated)
§ Educate patients and providers on signs and symptoms
of TB

TB/HIV Pearls
§ When treating active TB, work closely with TB Control
nurses, case managers, outreach workers
§ Give TB/HIV medications together when able
§ After completion of TB therapy, ensure continuation of
HIV care and maintained virologic suppression

§ Thank you!

US TB Cases, 2017: 9093

Tuberculosis—United States, 2017. MMWR 2018;76:[317-323]

http://www.tstin3d.com/en/calc.html

Questions / Answers

Thank You

